China Medical System Holdings (867) Stock Overview
An investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 867 from our risk checks.
867 Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
China Medical System Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$14.33 |
| 52 Week High | HK$15.63 |
| 52 Week Low | HK$6.84 |
| Beta | 1.27 |
| 1 Month Change | 7.74% |
| 3 Month Change | 9.31% |
| 1 Year Change | 73.07% |
| 3 Year Change | 13.73% |
| 5 Year Change | -15.11% |
| Change since IPO | 376.40% |
Recent News & Updates
Recent updates
China Medical System Holdings (HKG:867) Could Easily Take On More Debt
Dec 09
China Medical System Holdings Limited (HKG:867) Shares Could Be 43% Below Their Intrinsic Value Estimate
Jul 29China Medical System Holdings Limited's (HKG:867) Shareholders Might Be Looking For Exit
Jul 07Is China Medical System Holdings (HKG:867) A Risky Investment?
Apr 06Investors Continue Waiting On Sidelines For China Medical System Holdings Limited (HKG:867)
Jan 07Earnings Tell The Story For China Medical System Holdings Limited (HKG:867) As Its Stock Soars 26%
Sep 30Little Excitement Around China Medical System Holdings Limited's (HKG:867) Earnings
Jul 15An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 20% Undervalued
May 22China Medical System Holdings (HKG:867) Is Paying Out Less In Dividends Than Last Year
May 03We Think Shareholders May Want To Consider A Review Of China Medical System Holdings Limited's (HKG:867) CEO Compensation Package
May 02China Medical System Holdings' (HKG:867) Shareholders Will Receive A Smaller Dividend Than Last Year
Apr 19China Medical System Holdings (HKG:867) Is Paying Out Less In Dividends Than Last Year
Mar 29Not Many Are Piling Into China Medical System Holdings Limited (HKG:867) Stock Yet As It Plummets 35%
Mar 28China Medical System Holdings Limited's (HKG:867) Share Price Not Quite Adding Up
Dec 21Is China Medical System Holdings (HKG:867) A Risky Investment?
Dec 04If EPS Growth Is Important To You, China Medical System Holdings (HKG:867) Presents An Opportunity
Nov 15China Medical System Holdings (HKG:867) Will Pay A Larger Dividend Than Last Year At CN¥0.342
Aug 31China Medical System Holdings (HKG:867) Could Easily Take On More Debt
Aug 30Here's Why We Think China Medical System Holdings (HKG:867) Might Deserve Your Attention Today
Aug 07We Think China Medical System Holdings (HKG:867) Can Manage Its Debt With Ease
May 14Does China Medical System Holdings (HKG:867) Deserve A Spot On Your Watchlist?
Apr 26An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 47% Undervalued
Feb 05China Medical System Holdings (HKG:867) Seems To Use Debt Rather Sparingly
Dec 26If EPS Growth Is Important To You, China Medical System Holdings (HKG:867) Presents An Opportunity
Dec 08Is China Medical System Holdings (HKG:867) Using Too Much Debt?
Sep 14China Medical System Holdings (HKG:867) Is Paying Out A Larger Dividend Than Last Year
Aug 25Shareholder Returns
| 867 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 11.3% | 11.0% | -0.3% |
| 1Y | 73.1% | 42.1% | 14.8% |
Return vs Industry: 867 exceeded the Hong Kong Pharmaceuticals industry which returned 42.1% over the past year.
Return vs Market: 867 exceeded the Hong Kong Market which returned 14.8% over the past year.
Price Volatility
| 867 volatility | |
|---|---|
| 867 Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in HK Market | 14.8% |
| 10% least volatile stocks in HK Market | 3.4% |
Stable Share Price: 867 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 867's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 6,095 | Kong Lam | web.cms.net.cn/zh/home/ |
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. The company offers cardio-cerebrovascular products include VELPHORO, a sucroferric oxyhydroxide chewable tablets and diazepam nasal spray for seizure clusters; XinHuoSu, a recombinant human brain natriuretic peptide for acute heart failure; Plendil, a felodipine sustained release tablets for hypertension; and Deanxit, a flupentixol and melitracen tablets for mild-to-moderate depression. It also provides gastroenterology products, such as METOJECT, a methotrexate injection to treat severe recalcitrant disabling psoriasis and rheumatoid arthritis; LUMEBLUE, a methylthioninium chloride enteric-coated sustained-release tablets for colorectal lesion visualization; Salofalk for ulcerative colitis and Crohn’s disease; Bioflor, a saccharomyces boulardii sachets for diarrhea; Combizym and Cidine for digestive enzymes; and Ursofalk, a ursodeoxycholic acid capsules to treat cholesterol gallstones.
China Medical System Holdings Limited Fundamentals Summary
| 867 fundamental statistics | |
|---|---|
| Market cap | HK$33.48b |
| Earnings (TTM) | HK$1.69b |
| Revenue (TTM) | HK$9.35b |
Is 867 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 867 income statement (TTM) | |
|---|---|
| Revenue | CN¥8.21b |
| Cost of Revenue | CN¥2.34b |
| Gross Profit | CN¥5.87b |
| Other Expenses | CN¥4.38b |
| Earnings | CN¥1.49b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.62 |
| Gross Margin | 71.50% |
| Net Profit Margin | 18.13% |
| Debt/Equity Ratio | 3.7% |
How did 867 perform over the long term?
See historical performance and comparisonDividends
Does 867 pay a reliable dividends?
See 867 dividend history and benchmarks| China Medical System Holdings dividend dates | |
|---|---|
| Ex Dividend Date | Apr 27 2026 |
| Dividend Pay Date | May 07 2026 |
| Days until Ex dividend | 24 days |
| Days until Dividend pay date | 34 days |
Does 867 pay a reliable dividends?
See 867 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/02 10:57 |
| End of Day Share Price | 2026/04/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
China Medical System Holdings Limited is covered by 28 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jessica Li | BofA Global Research |
| Lok Kwan Chiu | CCB International Securities Limited |
| Harry He | China Galaxy International Securities (Hong Kong) |